36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Pauligk, C.; Tannapfel, A.; Meiler, J.; Luley, K.B.; Kopp, H.G.; Homann, N.; Hofheinz, R.D.; Schmalenberg, H.; Probst, S.; Haag, G.M.; Egger, M.; Behringer, D.M.; Stoehlmacher, J.; Prasnikar, N.; Block, A.; Trojan, J.; Folprecht, G.; Pohl, M.; Schirmacher, P.; Al-Batran, S.E.
• Is Part Of: European journal of cancer. Volume 51:Issue 3(2015:Feb.)
• Page Start: S728
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(15)30080-0
• Languages: English
• ISSNs: 0959-8049